UNIGE document Scientific Article
previous document  unige:89772  next document
add to browser collection

Hémostase : nouveaux anticoagulants oraux : de la théorie à la pratique

Published in Revue médicale suisse. 2013, vol. 9, no. 369, p. 104-107
Abstract Physicians are confronted with many new antithrombotic drugs, either antiplatelet agents or new oral anticoagulants (NOAC). Targets of NOAC are specific (either anti-IIa or antiXa) and clinical studies have shown that NOAC are as efficacious and as safe as "old" anticoagulants (heparin, low molecular weight heparin, vitamin K antagonists); moreover they present some advantages. Indeed, NOAC have a wide therapeutic window and do not require laboratory monitoring. Therefore, it is very tempting to prescribe them on a large scale basis in patients at risk or having thromboembolic diseases. However, things are not so simple in the day-to-day practice and this review aims at answering in a brief and simplified manner to some questions.
Keywords Administration, OralAnticoagulants/therapeutic useCreatinine/urineDrug InteractionsHumansSurgical Procedures, OperativeVitamin K/antagonists & inhibitors
PMID: 23409645
Full text
Article (Accepted version) (513 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Geneva Platelet Group (13)
(ISO format)
DE MOERLOOSE, Philippe et al. Hémostase : nouveaux anticoagulants oraux : de la théorie à la pratique. In: Revue médicale suisse, 2013, vol. 9, n° 369, p. 104-107. https://archive-ouverte.unige.ch/unige:89772

267 hits

0 download


Deposited on : 2016-12-02

Export document
Format :
Citation style :